Search the Newsreel

Wall Street Zen Upgrades Editas Medicine (NASDAQ:EDIT) to Hold

Wall Street Zen has upgraded Editas Medicine (NASDAQ:EDIT) from "sell" to "hold." Despite this, broader analyst coverage remains "Moderate Buy" with a consensus price target of $5.40. The company recently surpassed quarterly earnings and revenue expectations, although company insiders have sold shares while institutional …

Editas Medicine director Ellinor Patrick Thomas II files initial beneficial ownership statement

Editas Medicine director Ellinor Patrick Thomas II has filed an initial beneficial ownership statement (Form 3) with the SEC, dated August 6. This filing indicates that Thomas is now a reporting owner for the company. The news brief was generated by Public Technologies (PUBT) …

Investcorp Credit Management BDC Inc (ICMB) Earnings Forecast: Future EPS & Revenue Growth Estimates

This article provides an earnings forecast for Investcorp Credit Management BDC Inc (ICMB), detailing future EPS and revenue growth estimates. It notes that no earnings forecast score is available for ICMB, contrasting with an industry average, and provides an analyst rating of "Hold" based …

Accenture (ACN) Following UniCredit Deal And IBM Tie Up Has A Valuation Split

Find winning stocks in any market cycle. Join 7 million investors using Simply Wall St's investing ideas for FREE. Accenture (ACN) is back in focus after UniCredit announced a long term collaboration with Accenture and IBM that includes Accenture acquiring a majority stake in …

Editas Medicine (NASDAQ: EDIT) grants director 103400 options at $2.9000

Editas Medicine (NASDAQ: EDIT) reported that director Ellinor Patrick Thomas II was granted 103,400 stock options with an exercise price of $2.9000 per share, expiring on August 5, 2036. These options vest in three equal annual installments starting August 6, 2027. Following this grant, …

Editas Medicine, Inc. (EDIT) director reports no share or option holdings

A director at Editas Medicine, Inc. (EDIT), Ellinor Patrick Thomas II, has filed an initial beneficial ownership report (Form 3) disclosing no holdings of common stock or derivative securities. The filing indicates no insider transaction activity, such as purchases or sales, associated with this …

Expeditors International of Washington Inc (EXPD) director gifts 1,400 shares to charity

Diane H. Gulyas, a director at Expeditors International of Washington Inc (EXPD), reported a bona fide gift of 1,400 common stock shares to a charitable fund on August 6, 2026. The shares, valued at $178.56 each, were held indirectly via a trust. Following this …

All You Need to Know About Credit Acceptance (CACC) Rating Upgrade to Buy

Investors might want to bet on Credit Acceptance (CACC), as it has been recently upgraded to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful forces impacting stock prices -- has triggered this rating change. The …

Editas Medicine (EDIT) Stock Rallies On Revenue Jump But Losses Linger

Editas Medicine (EDIT) saw its stock rally by about 5% after reporting Q2 2026 earnings, driven by a significant increase in revenue to US$11.89 million from US$3.58 million year-on-year. While the company is still reporting losses, these narrowed to US$18.23 million from US$53.24 million, …

Credit Bureau Asia (SGX:TCU) Stock Steady Earnings Leave Valuation Questions Open

Credit Acceptance Corp (CACC) Stock News Today

This article provides the current stock information for Credit Acceptance Corp (CACC), including its real-time price, market capitalization, and P/E ratio. It indicates that more news will be coming soon, and directs users to TradingKey for updates on earnings, analyst ratings, and key developments.

FS Credit Opportunities Corp. (FSCO) Files 8-K Report: Key Details, Address, and NYSE Listing Information

FS Credit Opportunities Corp. (FSCO) filed an 8-K report announcing the adjournment of its 2026 Annual Meeting of Stockholders due to a lack of quorum for a director election. The meeting, which will reconvene on September 8, 2026, will address the sole agenda item …

Credit Corp Group (ASX:CCP) Could Be 28% Undervalued Following Full Year Earnings

FS Credit Opportunities (NYSE: FSCO) posts 2026 director vote, adjourns item

FS Credit Opportunities Corp. (NYSE: FSCO) reported the voting results from its August 3, 2026 Annual Meeting of Stockholders. Walter W. Buckley, III was elected as a director, but the election for Barbara J. Fouss was adjourned due to a lack of preferred stockholder …

Why Lindblad Expeditions Holdings (LIND) Is Up 14.4% After Returning To First-Half Profitability And Raising Guidance

Can Credit Corp Group (ASX:CCP) Turn Better Earnings Conversion Into a Bigger Growth Story?

FS Global Credit Opportunities Fund Plans Q2 Results Release

FS Global Credit Opportunities Fund (FSCO) announced plans to release its second-quarter financial results for the period ended June 30, 2026, after market close on Tuesday, August 25, 2026. The company will also publish an earnings presentation on its investor relations website and a …

Insider Kenneth S. Booth of CACC (NASDAQ: CACC) plans sale of 2,547 shares

Kenneth S. Booth, an insider at CACC, has filed a Form 144 notice indicating his intention to sell 2,547 shares of common stock on or after August 6, 2026. This planned sale is connected to a stock option exercise for cash. The filing also …

US$36.60 - That's What Analysts Think Lindblad Expeditions Holdings, Inc. (NASDAQ:LIND) Is Worth After These Results

Lindblad Expeditions Holdings, Inc. (LIND) reported Q2 results that exceeded analyst expectations for revenue and losses per share. Despite a minor downgrade to 2026 EPS forecasts, analysts increased the consensus price target by 30% to US$36.60, suggesting a positive long-term outlook. However, revenue growth …

Lindblad Expeditions Stock Has Exceptional Momentum at All-Time Highs

Cruise ship docked on beach by Georgy Trofimov via Unsplash Lindblad Expeditions (LIND) demonstrates exceptional momentum, gaining 160% over the past year. Shares recently hit a new all-time high. LIND holds a 100% "Buy" technical opinion from Barchart and has strong recent price appreciation. …

EDIT Q2 Earnings Beat Estimates, Revenues Rise, Pipeline in Focus

Editas Medicine (EDIT) reported a narrower-than-expected loss of 15 cents per share in Q2 2026, with revenues significantly surpassing estimates at $11.9 million due to deferred revenues. The company's lead gene-editing candidate, EDIT-401, for heterozygous familial hypercholesterolemia, showed encouraging preclinical data with rapid and …

Editas Medicine, Inc. 2026: Revenue $11.89M, EPS ($0.15) — 10-Q Summary

Editas Medicine, Inc. reported an increase in collaboration and research revenue to $11.89M for the quarter ended 2026, with a reduced net loss of ($18.23M) and improved diluted EPS of ($0.15). Key highlights include the nomination of EDIT-401 as the lead in vivo candidate …

Deutsche Bank Adjusts Lindblad Expeditions PT to $29 From $24, Maintains Hold Rating

Deutsche Bank has increased its price target for Lindblad Expeditions Holdings, Inc. (LIND) to $29 from $24, while retaining a "Hold" rating on the stock. This adjustment follows Lindblad Expeditions' strong Q2 results, which surpassed consensus expectations, and an upward revision of its 2026 …

Why Lindblad Expeditions (LIND) Is Up 14.4% After Q2 Profitability Gains And Buyback Completion

Higher Profit Conversion In FY26 Could Be A Game Changer For Credit Corp Group (ASX:CCP)

Credit Acceptance (CACC) Stock Shrugs Off Profit Surge As Credit Questions Linger

Carl Zeiss Meditec AG gibt Ergebnisprognose für das Jahr 2026 ab

Press Release: Editas Medicine Announces Second Quarter 2026 Results and Business Updates

Editas Medicine (NASDAQ: EDIT) announced its second quarter 2026 financial results and provided business updates. The company highlighted recent progress in its CRISPR-based therapeutic programs and discussed its financial position, offering insights into its strategic direction and upcoming milestones for the remainder of the …

Lindblad Expeditions Earnings Call Highlights Robust Growth

Lindblad Expeditions (LIND) reported robust Q2 2026 growth, with total revenue climbing 18.6% year-over-year and adjusted EBITDA jumping 30.7%. The company highlighted record net yields, 91% occupancy, and strong booking momentum for future years, despite facing headwinds from fuel inflation and increased operating costs. …

Expeditors' Net Revenue Growth Soaring On Robust Tech-Related Airfreight Demand

Expeditors International, a top global freight forwarder, is experiencing soaring net revenue growth driven by robust tech-related airfreight demand. The company's asset-light model and strong network effect contribute to its impressive financial performance, yielding nearly 35% returns on capital over the past decade. This …

Editas Medicine (NASDAQ:EDIT) Issues Earnings Results

Editas Medicine (NASDAQ:EDIT) announced its quarterly earnings, reporting an adjusted loss of $0.15 per share, surpassing the consensus estimate of a $0.27 loss, with revenue of $11.89 million, significantly exceeding analyst expectations of $2.85 million. Despite beating revenue and EPS estimates, the company remains …

Editas Medicine (EDIT) Reports Q2 Loss, Beats Revenue Estimates

Editas Medicine (EDIT) reported a Q2 loss of $0.15 per share, surpassing the Zacks Consensus Estimate of a $0.3 loss and representing a 50% surprise. The company also beat revenue estimates with $11.89 million, significantly higher than the $3.58 million from the previous year. …

FSCO Announces Earnings Release and Conference Call Schedule for Second Quarter 2026

FS Credit Opportunities Corp. (FSCO) announced its second quarter 2026 financial results will be released after market close on Tuesday, August 25, 2026. An earnings presentation will be available on their Investor Relations website, and a recorded earnings call with a transcript will be …

Expeditors International of Washington (NASDAQ:EXPD) Price Target Raised to $210.00 at UBS Group

UBS Group has raised its price target for Expeditors International of Washington (NASDAQ:EXPD) to $210.00, maintaining a "buy" rating, following the transportation company's strong Q2 earnings beat. The company reported EPS of $2.03, exceeding the $1.69 consensus, and a 32.1% year-over-year revenue increase. While …

FS Credit Opportunities Corp. (NYSE: FSCO) schedules Q2 2026 results and call

FS Credit Opportunities Corp. (FSCO) has announced its Q2 2026 earnings schedule. The company will release its financial results for the quarter ended June 30, 2026, after market close on August 25, 2026, along with an earnings presentation. A recorded earnings call and transcript …

Editas Medicine (EDIT) CFO tax-related share sale executed under preset plan

Editas Medicine's CFO, Amy Parison, sold 678 shares of common stock at $2.58 per share on August 3, 2026. This transaction was executed under a pre-established Rule 10b5-1 plan to cover tax withholding obligations from restricted stock units that vested on August 1, 2026, …